Ilika plc with ticker (LON:IKA) now has a potential upside of 227.9% according to Berenberg Bank.
Berenberg Bank set a target price of 100 GBX for the company, which when compared to the Ilika plc share price of 31 GBX at opening today (26/04/2024) indicates a potential upside of 227.9%. Trading has ranged between 25 (52 week low) and 60 (52 week high) with an average of 221,915 shares exchanging hands daily. The market capitalisation at the time of writing is £49,282,436.
Ilika plc is a United Kingdom-based company. The Company is engaged in developing and commercializing its cutting-edge solid-state batteries. The Company develops and commercializes its thin-film Stereax miniature solid-state batteries for powering implantable medical devices and industrial wireless sensors (IIoT) in specialist environments, as well as progressing the development of its large-format Goliath cells for electric vehicles (EV) and cordless appliances. It has a secured lease of approximately 1,600 square meters property for Stereax manufacturing scale-up and installed over 340 square meters clean room facility. The Company is enabling solutions for applications, such as industrial Internet of things (IoT), MedTech, electric vehicles (EV) and consumer electronics. The Company has its operations in the United States of America, China and Israel.
Ilika plc 227.9% potential upside indicated by Berenberg Bank
- Written by: Charlotte Edwards
Find more news, interviews, share price & company profile here for:
Latest Company News
Ilika has given notice of its 2026 Annual General Meeting and said its annual report and AGM notice will be available shortly.
Ilika’s Stereax technology will be presented at MedTech Ireland 2026 as the company targets further opportunities in active implanted medical devices.
Ilika is advancing Goliath through testing and manufacturing scale-up while targeting shorter-cycle markets alongside longer-term electric vehicle adoption.
Ilika is building the manufacturing and licensing pathway needed to move its Goliath solid-state battery technology towards larger-scale commercial production.
Morphose Capital Partners’ Dr Tom McColm discusses Ilika’s FY26 results, the outlook for Stereax commercial revenues, progress with Goliath and potential opportunities in automotive, defence and e-bikes.
Ilika CEO Graeme Purdy discusses Stereax product revenue, planned M300 battery deliveries, Goliath 10Ah development, EV market trends and rising demand from the defence sector.
